

Resonance Health Ltd

ACN 006 762 492


Annual General Meeting

17 November 2010

Resonance Health Ltd (RHT)

- Solid growth in FerriScan sales volume
- Revenue growth of 18% in the clinical use of FerriScan
- Strong growth in the number of centres providing FerriScan world wide
- Novartis relationship developed representing significant FerriScan sales potential
- Pilot launched the dual cardiac / liver iron assessment
 - 30% increased revenue from participating customers
- Research and Development of future products advanced
- Cash on hand at end of financial year of \$2.1 million

FY 2010: FerriScan Growth up 29%



US Expansion

28 US hospitals provide FerriScan (100% ↑)



- 14 New US FerriScan Centres in FY 2009/2010
- 14 Pre-existing US FerriScan Centres
- 5 US centres in set up progress for FerriScan

FerriScan now available in 24 countries





Beyond FerriScan

Liver Disease Market Opportunity


- Liver disease is one of the top 10 causes of death in the US
- Liver disease is the only major cause of death still increasing year-on-year in the UK

Leading causes

- Viral Hepatitis – 170m world wide are infected with HepC
- Alcoholism
- Fatty liver disease – nearly 1/3 of American adults have FLD
- Excess iron

Liver disease can lead to liver fibrosis, liver cirrhosis and liver cancer

Liver Disease Progression




Liver Biopsy

Invasive Diagnostic Method for Fatty Liver and Liver Fibrosis

A small slender core of tissue is removed with a biopsy needle



Liver




ADAM.

New Product in Development

Liver Fat and Liver Fibrosis Measurement

- Proof of Concept Completed for Fat and Fibrosis
 - Study of 59 people completed with promising results
- USA Regulatory Submission for Liver Fat Measurement
 - 510k submission Q4 2010, 90 day approval process
- Fibrosis Test development
 - Clinical study of 30 patients to commence Dec 2010 - Q3 2011
- Next Steps
 - International product validation 2011/12
 - Regulatory approval submission late 2012
- Good partnership potential
 - most of the top 10 pharmaceutical companies developing therapies to address liver fibrosis

Resonance Health Product Portfolio



FY 2010: Financial Results

- Revenue associated with the routine clinical use of FerriScan grew 18% and continues to grow
- Revenue associated with the use of FerriScan in clinical trials declined, as some clinical trials using FerriScan were completed
- Research and development expenditure increased 64% to over \$500,000 to develop pipeline for future growth
- With revenue growth and new product partnerships, cash burn expected to decline

	2007-8	2008-9	2009-10
FerriScan Volumes	1605	2200	3042
FerriScan Revenue	\$1.7m	\$2.2m	\$1.8m
Net (Loss) A/ Tax	\$41k Loss	\$617k Profit	\$102k Loss
Year end Cash	\$2.4m	\$2.6m	\$2.1m



Summary

- Strong future for Resonance Health
- Solid growth in the commercial use of FerriScan
- Novartis relationship developed in global iron overload market
- Continued focus on gaining reimbursement for FerriScan
- Distributors engaged for entry into target regions
- Engagement with strong development partners in the areas of liver fibrosis and liver fat
- New liver diagnostic products with very large addressable markets